September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Sabine D. Brookman-May: Updated analysis with additional FU of EV 302 in 1st line advanced Bladder Cancer
Feb 18, 2025, 19:32

Sabine D. Brookman-May: Updated analysis with additional FU of EV 302 in 1st line advanced Bladder Cancer

Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:

“Updated analysis with additional FU of EV 302 EV+P in 1st line advanced Bladder Cancer.

  • PFS & OS benefit in all groups.
  • Benefit in cisplatin eligible/ineligible.
  • Safety consistent with prior analysis.
  • mDOR close to 2 years.

 Sabine D. Brookman-May: Updated analysis with additional FU of EV 302 in 1st line advanced Bladder Cancer